The Role of Genetic Factors in the Development of Individual Predisposition to Ischemic Stroke

Korchagin, V. I.; Миронов, К. О.; Дрибноходова, О. П.; Maksimova, M. Yu.; Иллариошкин, С.Н.; Tanashyan, M. M.; Platonov, Alexander E.; Shipulin, German A.; Raskurazhev, A. A.; Piradov, М. А.

doi:10.1134/s0362119717080047

Cited by 8 publications

(4 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…и ассоциирована с тяжелым течением и частыми рецидивами венозного тромбоза. В нашей стране для пациентов с криптогенным ишемическим инсультом предусмотрен скрининг тромбофилических состояний (в том числе мутаций гена протромбина G20210A и фактора V Лейдена) [8,9,[38][39][40][41][42][43][44][45][46].…”

Section: сердечно-сосудистые заболевания в семейном анамнезеunclassified

Genetic factors of thrombosis FII G20210A, FV G1691A (Arg506Gln) in patients with thoracoabdominal malignant tumors

Korolyova,

Gerasimov,

Lyubchenko

2024

Usp. mol. onkol

View full text Add to dashboard Cite

Introduction. Malignant tumor is one of the leading factors of venous and arterial thrombosis. But there is no data on the need for a genetic testing protocol of cancer patients for genetic predisposition thrombotic conditions, despite the fact that a number of polymorphisms of hemostasis genes are considered to be unconditionally proven factors of high cumulative thrombogenic risk, and proteins encoded by these genes are direct links in the cascades of pathological hypercoagulation in neoplastic processes.Aim. To identify groups of high genetic risk of thrombotic complications among patients with malignant thoracoabdominal tumors.Materials and methods. The study included 223 patients with malignant tumors of the lung, stomach, esophagus, operated in the Department of Thoracic Oncology of the N.N. Blokhin National Research Center of Oncology in 2018–2019. The study groups consisted of patients with myocardial infarction (n = 62), ischemic stroke (n = 24), venous thrombosis/ venous thromboembolic complications (n = 40), patients without cardiovascular diseases, but with a family history burdened by cardiovascular diseases (n = 33). The control group included 81 patients.Results. Among patients with malignant tumors of thoracoabdominal localization, a statistically significant difference was determined in the frequency of carriage of the heterozygous genotype FV 1691GA (Arg506Gln) in patients who had a myocardial infarction (χ2 = 4.0; p = 0.046), who had venous thrombosis (χ2 = 4.118; p = 0.043), in the group of patients with burdened with a family history (χ2 = 4.997; p = 0.026) in comparison with the control group. Statistically significant difference in the frequency of carriage of the heterozygous variant of the mutation in the FII G20210A gene relative to the control group, it was determined in the group of patients who had an acute cerebrovascular accident (χ2 = 6.881; p = 0.009) and among patients with a burdened history (χ2 = 7.563; p = 0.006).Conclusion. In order to assess the risk of development and prevention of thrombotic complications in the perioperative period in patients with malignant thoracoabdominal tumors, who have suffered myocardial infarction, ischemic stroke, venous thrombosis/venous thromboembolic complications, as well as patients without cardiovascular pathology, but with thrombotic conditions in relatives of the first degree, it is advisable to perform DNA diagnostics at the prehospital stage to identify of gene polymorphisms FII G20210A and FV G1691A (Arg506Gln).

show abstract

Section: сердечно-сосудистые заболевания в семейном анамнезеunclassified

Genetic factors of thrombosis FII G20210A, FV G1691A (Arg506Gln) in patients with thoracoabdominal malignant tumors

Korolyova,

Gerasimov,

Lyubchenko

2024

Usp. mol. onkol

View full text Add to dashboard Cite

show abstract

“…It should be noted that after a stroke, not only motor disorders occur. Immediately after the acute period of stroke, 36% of patients have speech disorders (aphasia) [16]. The main factors causing the death of neurons after ischemia are oxygen and glucose deprivation, resulting in oxidative stress, acidosis, and glutamate cytotoxicity.…”

Section: Antioxidant Properties Of Thymoquinone In Brain Ischemia Modelsmentioning

confidence: 99%

Antioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases

2023

View full text Add to dashboard Cite

Oxidative stress is one of the main pathogenic factors of neuron damage in neurodegenerative processes; this makes it an important therapeutic target to which the action of neuroprotectors should be directed. One of these drugs is thymoquinone. According to modern data, this substance has a wide range of pharmacological activity, including neuroprotective, which was demonstrated in experimental modeling of various neurodegenerative diseases and pathological conditions of the brain. The neuroprotective effect of thymoquinone is largely due to its antioxidant ability. Currently available data show that thymoquinone is an effective means to reduce the negative consequences of acute and chronic forms of cerebral pathology, leading to the normalization of the content of antioxidant enzymes and preventing an increase in the level of lipid peroxidation products. Antioxidant properties make this substance a promising basis for the development of prototypes of therapeutic agents aimed at the treatment of a number of degenerative diseases of the central nervous system.

show abstract

“…Among these articles, seven were subsequently excluded: three reported on non-Asians, 5,16,17 two reported on overlapping populations 18,19 and two were reviews. 20,21 The authors of 3 articles (Liu et al 14,22 and Wu et al 23) needed to be contacted, and the authors of only two articles (Liu et al 14,22) provided detailed data. Finally, ten studies (in seven articles involving 3644 IS patients and 3692 controls) were included in the meta-analysis on rs556621 and IS risk (Table 1).…”

Section: Eligible Studiesmentioning

confidence: 99%

Variant Rs556621 on Chromosome 6p21.1 and the Risk of Ischemic Stroke in Chinese Populations: A Meta-Analysis

Chen

Zhang

et al. 2022

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

There are inconsistencies in the published findings on the association of variant rs556621 in an intergenic region on Chromosome 6p21.1 with the risk of developing ischemic stroke (IS) and a major IS subtype (large artery atherosclerosis, LAA) in Chinese populations. We conducted a meta-analysis to evaluate the association of variant rs556621 with IS/LAA risk using ten studies involving 3644 IS cases and 3692 controls (including seven studies involving 2268 LAA cases and 2268 controls) from China. The AA genotype increased IS risk (AA versus CC: odds ratio [OR] 1.19, 95% confidence interval [CI] 1.03-1.36, P = 0.015; AA versus CA + CC: OR 1.23, 95% CI 1.09-1.39, P = 0.001). Subgroup analysis also suggested that rs556621 contributed to the risk of IS both in Chinese Han and the miscellaneous group. However, these results were stable in Chinese Han but not in the miscellaneous group. When restricting our analysis to the LAA subtype, similar results were obtained. This meta-analysis is the first meta-analysis on the correlation between rs556621 and the susceptibility of IS/LAA and demonstrates that rs556621 is associated with IS/LAA risk in Chinese populations. Further meta-analysis warrants larger well-designed investigations to assess these effects.

show abstract

The Role of Genetic Factors in the Development of Individual Predisposition to Ischemic Stroke

Cited by 8 publications

References 97 publications

Genetic factors of thrombosis <i>FII G20210A</i>, <i>FV G1691A</i> (<i>Arg506Gln</i>) in patients with thoracoabdominal malignant tumors

Genetic factors of thrombosis <i>FII G20210A</i>, <i>FV G1691A</i> (<i>Arg506Gln</i>) in patients with thoracoabdominal malignant tumors

Antioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases

Variant Rs556621 on Chromosome 6p21.1 and the Risk of Ischemic Stroke in Chinese Populations: A Meta-Analysis

Contact Info

Product

Resources

About